IL-1β, RAGE and FABP4: Targeting the dynamic trio in metabolic inflammation and related pathologies

Future Medicinal Chemistry

Volumn 5, Issue 10, 2013, Pages 1089-1108

  Hardaway, Aimalie L ^a   Podgorski, Izabela ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; AMINOGUANIDINE; AREALYST; ATORVASTATIN; CANAKINUMAB; CATHEPSIN G; DEXAMETHASONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID BINDING PROTEIN 4; GEVOKIZUMAB; GRANZYME A; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; METFORMIN; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PF 4494700; PRILACE; PROTEIN; PROTEIN RAGE; PYRIDORIN; RAMIPRIL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SIMVASTATIN; SITAGLIPTIN; TRC 4186; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANAEROBIC METABOLISM; ATHEROSCLEROSIS; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL METABOLISM; DISEASE SEVERITY; ENDOPLASMIC RETICULUM STRESS; ENTERITIS; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; GLYCOLYSIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; LIPID METABOLISM; METABOLISM; MONONUCLEAR PHAGOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; FATTY ACID-BINDING PROTEINS; HUMANS; INFLAMMASOMES; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-1BETA; METABOLIC DISEASES; NEOPLASMS; NF-KAPPA B; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 84879643613     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.90     Document Type: Review

References (192)

1. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415-445 (2011).
2. Shu CJ, Benoist C, Mathis D. The immune system's involvement in obesity-driven Type 2 diabetes. Semin. Immunol. 24(6), 436-442 (2013).
3. Tanti JF, Ceppo F, Jager J, Berthou F. Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Front. Endocrinol. (Lausanne) 3, 181 (2012).
4. Weisberg SP, Mccann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112(12), 1796-1808 (2003). (Pubitemid 38063703)
5. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15(5), 635-645 (2012).
6. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 7(6), 489-503 (2008). (Pubitemid 351767117)
7. Makowski L, Hotamisligil GS. Fatty acid binding proteins-the evolutionary crossroads of inflammatory and metabolic responses. J. Nutr. 134(9), 2464S-2468S (2004). (Pubitemid 39201622)
8. Alexiou P, Chatzopoulou M, Pegklidou K, Demopoulos VJ. RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr. Med. Chem. 17(21), 2232-2252 (2010).
9. Sparvero LJ, Asafu-Adjei D, Kang R et al. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med. 7(17), 17 (2009).
10. Tomino Y, Hagiwara S, Gohda T. AGE-RAGE interaction and oxidative stress in obesity-related renal dysfunction. Kidney Int. 80(2), 133-135 (2011).
11. Furuhashi M, Tuncman G, Görgün C et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447(7147), 959-965 (2007). (Pubitemid 46975747)
12. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J. Clin. Invest. 116(7), 1793-1801 (2006). (Pubitemid 44033299)
13. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67(20), 10019-10026 (2007). (Pubitemid 47621253)
14. Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss JM. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res. Treat 119(2), 367-377 (2010).
15. Nieman K, Kenny H, Penicka C et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17(11), 1498-1503 (2011).
16. Riehl A, Nemeth J, Angel P, Hess J. The receptor RAGE: bridging inflammation and cancer. Cell Commun. Signal. 7, 12 (2009).
17. Tu S, Bhagat G, Cui G et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14(5), 408-419 (2008).
18. Voronov E, Shouval DS, Krelin Y et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl Acad. Sci. USA 100(5), 2645-2650 (2003). (Pubitemid 36297552)
19. Besedovsky H, Del Rey A, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 233(4764), 652-654 (1986). (Pubitemid 16011614)
20. Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: role in Type 2 diabetes. Clinical Chim. Acta 413(15-16), 1163-1170 (2012).
21. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. Inflammasome activation and IL-1b and IL-18 processing during infection. Trends Immunol. 32(3), 110-116 (2011).
22. Li N, Karin M. Is NF-kappaB the sensor of oxidative stress? FASEB J. 13(10), 1137-1143 (2012).
23. Dinarello CA, Simon A, Van Der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11(8), 633-652 (2012).
24. Agostini L, Martinon F, Burns K, Mcdermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20(3), 319-325 (2004). (Pubitemid 38388233)
25. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009).
26. Jagielska J, Kapopara P, Salguero G et al. Interleukin-1 assembles a proangiogenic signaling module consisting of caveolin-1, tumor necrosis factor receptor-associated factor 6, p38-mitogen-activated protein kinase (MAPK), and MAPK-activated protein kinase 2 in endothelial cells. Atheroscler. Thromb. Vasc. Biol. 32(5), 1280-1288 (2012).
27. Matsuki T, Horai R, Sudo K, Iwakura Y. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J. Exp. Med. 198(6), 877-888 (2003). (Pubitemid 37152925)
28. Speaker K, Fleshner M. Interleukin-1 beta: a potential link between stress and the development of visceral obesity. BMC Physiol. 12:8 (2012).
29. Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur. J. Immunol. 41(5), 1203-1217 (2011).
30. Dinarello C. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14) 3720-3732 (2011).
31. Maedler K, Dharmadhikari G, Schumann D, Størling J. Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes. Handb. Exp. Pharmacol. 203, 257-278 (2011).
32. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 28, 367-388 (2010).
33. Schmidt AM, Vianna M, Gerlach M et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267(21), 14987-14997 (1992).
34. Lin L, Zhong K, Sun Z, Wu G, Ding G. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J. Cancer Res. Clin. Oncol. 138(1), 1-22 (2012).
35. Kalea AZ, Schmidt AM, Hudson BI. Alternative splicing of RAGE: roles in biology and disease. Front. Biosci. 16, 2756-2770 (2011).
36. Rojas A, Figueroa H, Morales E. Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis 31(3), 334-341 (2010).
37. Bierhaus A, Humpert PM, Morcos M et al. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. (Berl.) 83(11), 876-886 (2005). (Pubitemid 41598688)
38. Raucci A, Cugusi S, Antonelli A et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 22(10), 3716-3727 (2008).
39. Tang D, Kang R, Xiao W et al. Nuclear heat shock protein 72 as a negative regulator of oxidative stress (hydrogen peroxide)-induced HMGB1 cytoplasmic translocation and release. J. Immunol. 178(11), 7376-7384 (2007). (Pubitemid 46847465)
40. Tian J, Avalos AM, Mao SY et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8(5), 487-496 (2007). (Pubitemid 46605917)
41. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J. Clin. Endocrinol. Metab. 93(6), 2042-2049 (2008). (Pubitemid 351831513)
42. Urbonaviciute V, Furnrohr BG, Meister S et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205(13), 3007-3018 (2008).
43. Coffelt SB, Scandurro AB. Tumors sound the alarmin(s). Cancer Res. 68(16), 6482-6485 (2008).
44. Abeyama K, Stern DM, Ito Y et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 115(5), 1267-1274 (2005). (Pubitemid 40629045)
45. Yamamoto Y, Harashima A, Saito H et al. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J. Immunol. 186(5), 3248-3257 (2011).
46. Cataldegirmen G, Zeng S, Feirt N et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J. Exp. Med. 201(3), 473-484 (2005). (Pubitemid 40229421)
47. Bucciarelli LG, Kaneko M, Ananthakrishnan R et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 113(9), 1226-1234 (2006).
48. Ramasamy R, Yan S, Schmidt A. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann. NY Acad. Sci. 1243, 88-102 (2011).
49. Garlanda C, Riva F, Polentarutti N et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc. Natl Acad. Sci. USA 101(10), 3522-3526 (2004). (Pubitemid 38338228)
50. Lin L. RAGE on the Toll Road? Cell Mol. Immunol. 3(5), 351-358 (2006).
51. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181(7), 4666-4675 (2008).
52. Nguyen DV, Shaw LC, Grant MB. Inflammation in the pathogenesis of microvascular complications in diabetes. Front. Endocrinol. (Lausanne) 3, 170 (2012).
53. Riboldi E, Porta C, Morlacchi S, Viola A, Mantovani A, Sica A. Hypoxia-mediated regulation of macrophage functions in pathophysiology. Int. Immunol. 25(2), 67-75 (2012).
54. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 148(3), 399-408 (2012).
55. Mazzatti D, Lim FL, O'Hara A, Wood IS, Trayhurn P. A microarray analysis of the hypoxia-induced modulation of gene expression in human adipocytes. Arch. Physiol. Biochem. 118(3), 112-120 (2012).
56. Kalupahana NS, Claycombe KJ, Moustaid-Moussa N. (n-3) fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. Adv. Nutr. 2(4), 304-316 (2011).
57. Youm Y, Adijiang A, Vandanmagsar B, Burk D, Ravussin A, Dixit V. Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology 152(11), 4039-4045 (2011).
58. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 20(3), 237-250 (2003). (Pubitemid 36513228)
59. Yan W, Chang Y, Liang X et al. High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 55(6), 1863-1875 (2012).
60. Engelen L, Stehouwer CD, Schalkwijk CG. Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes Obes. Metab. doi:10.1111/dom.12058 (2012) (Epub ahead of print).
61. Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15(7), 16R-28R (2005). (Pubitemid 41417992)
62. Kranstuber AL, Del Rio C, Biesiadecki BJ et al. Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling. Front. Physiol. 3, 292 (2012).
63. Del Turco S, Basta G. An update on advanced glycation endproducts and atherosclerosis. Biofactors 38(4), 266-274 (2012).
64. Chang JC, Kou SJ, Lin WT, Liu CS. Regulatory role of mitochondria in oxidative stress and atherosclerosis. World J. Cardiol. 2(6), 150-159 (2010).
65. Yan S, Naka Y, Hudson B et al. The ligand/RAGE axis: lighting the fuse and igniting vascular stress. Curr. Atheroscler. Rep. 8(3), 232-239 (2006). (Pubitemid 43676327)
66. Weil Z. Ischemia-induced hyperglycemia: consequences, neuroendocrine regulation, and a role for RAGE. Horm. Behav. 62(3), 280-285 (2012).
67. Kamide T, Kitao Y, Takeichi T et al. RAGE mediates vascular injury and inflammation after global cerebral ischemia. Neurochem. Int. 60(3), 220-228 (2012).
68. Perrone L, Sbai O, Nawroth P, Bierhaus A. The complexity of sporadic alzheimer's disease pathogenesis: the role of RAGE as therapeutic target to promote neuroprotection by inhibiting neurovascular dysfunction. Int. J. Alzheimers Dis. doi:10.1155/2012/734956 (2012) (Epub ahead of print).
69. Robinson A, Johnson K, Bennion B, Reynolds P. RAGE signaling by alveolar macrophages influences tobacco smoke-induced inflammation. Am. J. Lung Cell Mol. Physiol. 302(11), L1192-L1199 (2012).
70. Curti M, Jacob P, Borges M, Rogero M, Ferreira S. Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approach. J. Obes. doi:10.1155/2011/497401 (2011) (Epub ahead of print).
71. Hotamisligil GS. Inflammation and metabolic disorders. Nature 444(7121), 860-867 (2006). (Pubitemid 46024993)
72. Lacraz G, Giroix M, Kassis N et al. Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat. PLoS ONE 4(9), e6963 (2009).
73. Stienstra R, Joosten L, Koenen T et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12(6), 593-605 (2010).
74. Petrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr. Opin. Immunol. 19(6), 615-622 (2007). (Pubitemid 350236810)
75. Stienstra R, Tack CJ, Kanneganti TD, Joosten LA, Netea MG. The inflammasome puts obesity in the danger zone. Cell Metab. 15(1), 10-18 (2012).
76. Wen H, Ting J, O'Neill L. A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nat. Immunol. 13(4), 352-357 (2012).
77. Böni-Schnetzler M, Donath M. Increased IL-1b activation, the culprit not only for defective insulin secretion but also for insulin resistance? Cell Res. 21(7), 995-997 (2011).
78. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112(12), 1821-1830 (2003). (Pubitemid 38063705)
79. Haraba R, Suica V, Uyy E, Ivan L, Antohe F. Hyperlipidemia stimulates the extracellular release of the nuclear high mobility group box 1 protein. Cell Tissue Res. 346(3), 361-368 (2011).
80. Henstridge D, Bruce C, Pang C et al. Skeletal muscle-specific overproduction of constitutively activated c-Jun N-terminal kinase (JNK) induces insulin resistance in mice. Diabetologia 55(10), 2769-2778 (2012).
81. Guan Z, Buckman S, Springer L, Morrison A. Both p38alpha(MAPK) and JNK/SAPK pathways are important for induction of nitric-oxide synthase by interleukin-1beta in rat glomerular mesangial cells. J. Biol. Chem. 274(51), 36200-36206 (1999).
82. Ortis F, Miani M, Colli M et al. Differential usage of NF-B activating signals by IL-1b and TNF-a in pancreatic beta cells. FEBS Lett. 586, 984-989 (2012).
83. Wieser V, Moschen A, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch. Immunol. Ther. Exp. 61(2), 119-125 (2013).
84. Carstensen M, Herder C, Kivimaki M et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 59(5), 1222-1227 (2010).
85. Ceriello A. The emerging challenge in diabetes: the "metabolic memory". Vascul. Pharmacol. 57(5-6), 133-138 (2012).
86. Gaziano T, Reddy KS, Paccaud F, Horton S, Chaturvedi V. Cardiovascular disease. In: Disease Control Priorities in Developing Countries. Jamison DT, Breman JG, Measham AR et al. (Eds). World Bank, Washington DC, USA, 646-662 (2006).
87. Lovren F, Pan Y, Quan A et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 126(11 Suppl. 1), S81-S90 (2012).
88. Yoda K, Imanishi Y, Yoda M et al. Impaired response of FGF-23 to oral phosphate in patients with Type 2 diabetes: a possible mechanism of atherosclerosis. J. Clin. Endocrinol. Metab. 97(11), E2036-E2043 (2012).
89. Koltsova E, Garcia Z, Chodaczek G et al. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J. Clin. Invest. 122(9), 3114-3126 (2012).
90. Chamberlain J, Francis S, Brookes Z et al. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS ONE 4(4), e5073 (2009).
91. Kirii H, Niwa T, Yamada Y et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23(4), 656-660 (2003). (Pubitemid 36438080)
92. Ben-Sasson S, Hu-Li J, Quiel J et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc. Natl Acad. Sci. USA 106(17), 7119-7124 (2009).
93. Loppnow H, Werdan K, Buerke M. Vascular cells contribute to atherosclerosis by cytokine-and innate-immunity-related inflammatory mechanisms. Innate Immun. 14(2), 63-87 (2008).
94. Chan W, Pejnovic N, Hamilton H et al. Atherosclerotic abdominal aortic aneurysm and the interaction between autologous human plaque-derived vascular smooth muscle cells, type 1 NKT, and helper T cells. Circ. Res. 96(6), 675-683 (2005). (Pubitemid 40478335)
95. Morigi M, Angioletti S, Imberti B et al. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J. Clin. Invest. 101(9), 1905-1915 (1998). (Pubitemid 28226110)
96. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA. RAGE biology, atherosclerosis and diabetes. Clin. Sci. (Lond.) 121(2), 43-55 (2011).
97. Harja E, Bu DX, Hudson BI et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/-mice. J. Clin. Invest. 118(1), 183-194 (2008).
98. Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4(9), 1025-1031 (1998). (Pubitemid 28417334)
99. Gao X, Zhang H, Schmidt AM, Zhang C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in Type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 295(2), H491-498 (2008).
100. Soro-Paavonen A, Watson AM, Li J et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57(9), 2461-2469 (2008).
101. Ueno H, Koyama H, Shoji T et al. Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse. Atherosclerosis 211(2), 431-436 (2010).
102. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 24(11), 2137-2142 (2004). (Pubitemid 39482442)
103. Lindsey JB, De Lemos JA, Cipollone F et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 32(7), 1218-1220 (2009).
104. Al-Mesallamy HO, Hammad LN, El-Mamoun TA, Khalil BM. Role of advanced glycation end product receptors in the pathogenesis of diabetic retinopathy. J. Diabetes Complications 25(3), 168-174 (2011).
105. Raposeiras-Roubin S, Rodino-Janeiro BK, Grigorian-Shamagian L et al. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: new roles for soluble RAGE. Eur. J. Heart Fail. 12(10), 1092-1100 (2010).
106. Guo ZS, Liu Z, Bartlett DL, Tang D, Lotze MT. Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am. J. Cancer Res. 3(1), 1-20 (2013).
107. Shanmugam N, Kim YS, Lanting L, Natarajan R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J. Biol. Chem. 278(37), 34834-34844 (2003). (Pubitemid 37102242)
108. Gebhardt C, Riehl A, Durchdewald M et al. RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med. 205(2), 275-285 (2008). (Pubitemid 351281593)
109. Turovskaya O, Foell D, Sinha P et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29(10), 2035-2043 (2008).
110. Apte SM, Vadhan-Raj S, Cohen L et al. Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. J. Transl. Med. 4, 16 (2006).
111. Elaraj DM, Weinreich DM, Varghese S et al. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin. Cancer Res. 12(4), 1088-1096 (2006). (Pubitemid 43342496)
112. Okamoto M, Liu W, Luo Y et al. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J. Biol. Chem. 285(9), 6477-6488 (2010).
113. Carmeliet P, Dor Y, Herbert JM et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394(6692), 485-490 (1998). (Pubitemid 28373960)
114. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 87(6), 2095-2147 (1996). (Pubitemid 26086851)
115. Song X, Krelin Y, Dvorkin T et al. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 175(12), 8200-8208 (2005). (Pubitemid 41798384)
116. Wang Y, Kato N, Hoshida Y et al. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 37(1), 65-71 (2003). (Pubitemid 36042146)
117. Zhang Y, Liu C, Peng H, Zhang J, Feng Q. IL1 receptor antagonist gene IL1-RN variable number of tandem repeats polymorphism and cancer risk: a literature review and meta-analysis. PLoS ONE 7(9), e46017 (2012).
118. Gu H, Yang L, Sun Q et al. Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population. Clin. Cancer Res. 14(11), 3627-3632 (2008).
119. Krechler T, Jachymova M, Mestek O, Zak A, Zima T, Kalousova M. Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin. Biochem. 43(10-11), 882-886 (2010).
120. Tesarova P, Kalousova M, Jachymova M, Mestek O, Petruzelka L, Zima T. Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest. 25(8), 720-725 (2007). (Pubitemid 350223177)
121. Gonzalez I, Romero J, Rodriguez BL, Perez-Castro R, Rojas A. The immunobiology of the receptor of advanced glycation end-products: trends and challenges. Immunobiology 218(5), 790-797 (2012).
122. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 365(9468), 1415-1428 (2005). (Pubitemid 40523737)
123. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 60(10), 2441-2449 (2011).
124. Yki-Jarvinen H. Ectopic fat accumulation: an important cause of insulin resistance in humans. J. R. Soc. Med. 95(Suppl. 42), 39-45 (2002). (Pubitemid 34879130)
125. Wilding JP. The importance of free fatty acids in the development of Type 2 diabetes. Diabet. Med. 24(9), 934-945 (2007). (Pubitemid 47304378)
126. Hertzel AV, Bernlohr DA. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol. Metab. 11(5), 175-180 (2000). (Pubitemid 30457137)
127. Roden M. Blocking fatty acids' mystery tour: a therapy for metabolic syndrome? Cell Metab. 6(2), 89-91 (2007). (Pubitemid 47163626)
128. Hotamisligil G, Johnson R, Distel R, Ellis R, Papaioannou V, Spiegelman B. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274(5291), 1377-1379 (1990).
129. Baar RA, Dingfelder CS, Smith LA et al. Investigation of in vivo fatty acid metabolism in AFABP/aP2(-/-) mice. Am. J. Physiol. Endocrinol. Metab. 288(1), E187-E193 (2005). (Pubitemid 40023806)
130. Makowski L, Brittingham K, Reynolds J, Suttles J, Hotamisligil G. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity: macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J. Biol. Chem. 13, 12888-12895 (2005).
131. Lowe CE, O'Rahilly S, Rochford JJ. Adipogenesis at a glance. J. Cell Sci. 124(Pt 16), 2681-2686 (2011).
132. Ayers SD, Nedrow KL, Gillilan RE, Noy N. Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPARgamma by FABP4. Biochemistry 46(23), 6744-6752 (2007). (Pubitemid 46906405)
133. Gillilan RE, Ayers SD, Noy N. Structural basis for activation of fatty acid-binding protein 4. J. Mol. Biol. 372(5), 1246-1260 (2007). (Pubitemid 47374720)
134. Damcott C, Moffett S, Feingold E et al. Genetic variation in fatty acid-binding protein-4 and peroxisome proliferator-activated receptor gamma interactively influence insulin sensitivity and body composition in males. Metabolism 53(3), 303-309 (2004). (Pubitemid 38684689)
135. Guilherme A, Virbasius J, Puri V, Czech M. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat. Rev. Mol. Cell Biol. 9(5), 367-377 (2008). (Pubitemid 351574198)
136. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2(10), 748-759 (2002). (Pubitemid 37328715)
137. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 6(3), 203-208 (2004).
138. Queipo-Ortuno MI, Escote X, Ceperuelo-Mallafre V et al. FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels. PLoS ONE 7(11), e48605 (2012).
139. Hresko RC, Hoffman RD, Flores-Riveros JR, Lane MD. Insulin receptor tyrosine kinase-catalyzed phosphorylation of 422(aP2) protein. Substrate activation by long-chain fatty acid. J. Biol. Chem. 265(34), 21075-21085 (1990). (Pubitemid 120014123)
140. Aragonès G, Saavedra P, Heras M, Cabré A, Girona J, Masana L. Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. Cardiovasular. Diabetol. 11(1), 72 (2012).
141. Ota H, Furuhashi M, Ishimura S et al. Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am. J. Hypertens. 25(10), 1124-1130 (2012).
142. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 339(6116), 172-177 (2013).
143. Wang X, Yang K, He Y, Lu L, Shen W. Receptor mediated elevation in FABP4 levels by advanced glycation end products induces cholesterol and triacylglycerol accumulation in THP-1 macrophages. Lipids 46(6), 479-486 (2011).
144. Karakas SE, Almario RU, Kim K. Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers. Metabolism 58(7), 1002-1007 (2009).
145. Nov O, Shapiro H, Ovadia H et al. Interleukin-1beta regulates fat-liver crosstalk in obesity by auto-paracrine modulation of adipose tissue inflammation and expandability. PLoS ONE 8(1), e53626 (2013).
146. Lagathu C, Yvan-Charvet L, Bastard J et al. Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia 49(9), 2162-2173 (2006). (Pubitemid 44168485)
147. Stienstra R, Mandard S, Tan NS et al. The interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver. J. Hepatol. 46(5), 869-877 (2007). (Pubitemid 46529035)
148. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 14(3-4), 222-231 (2008). (Pubitemid 351481853)
149. Bojic L, Sawyez C, Telford D, Edwards J, Hegele R, Huff M. Activation of peroxisome proliferator-activated receptor d inhibits human macrophage foam cell formation and the inflammatory response induced by very low-density lipoprotein. Atheroscler. Thromb. Vasc. Biol. 32(12), 2919-2928 (2012).
150. Fu Y, Luo L, Luo N, Garvey W. Lipid metabolism mediated by adipocyte lipid binding protein (ALBP/aP2) gene expression in human THP-1 macrophages. Atherosclerosis 188(1), 102-111 (2006). (Pubitemid 44142544)
151. Holm S, Ueland T, Dahl TB et al. Fatty Acid binding protein 4 is associated with carotid atherosclerosis and outcome in patients with acute ischemic stroke. PLoS ONE 6(12), e28785 (2011).
152. Kralisch S, Fasshauer M. Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia 56(1), 10-21 (2013).
153. Makowski L, Boord JB, Maeda K et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 7(6), 699-705 (2001). (Pubitemid 32588026)
154. Boiteux G, Lascombe I, Roche E et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int. J. Cancer 124(8), 1820-1828 (2009).
155. Das R, Hammamieh R, Neill R, Melhem M, Jett M. Expression pattern of fatty acid-binding proteins in human normal and cancer prostate cells and tissues. Clin. Cancer Res. 7(6), 1706-1715 (2001). (Pubitemid 32708639)
156. Tolle A, Suhail S, Jung M, Jung K, Stephan C. Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma. BMC Cancer 11, 302 (2011).
157. Elmasri H, Karaaslan C, Teper Y et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J. 23(11), 3865-3873 (2009).
158. Cataltepe O, Arikan MC, Ghelfi E et al. Fatty acid binding protein 4 is expressed in distinct endothelial and non-endothelial cell populations in glioblastoma. Neuropathol. Appl. Neurobiol. 38(5), 400-410 (2012).
159. Anghileri E, Eoli M, Paterra R et al. FABP4 is a candidate marker of cerebellar liponeurocytomas. J. Neurooncol. 108(3), 513-519 (2012).
160. Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss J. Adipocyte fatty acid-binding protein as a novel prognostic factor in obese breast cancer patients. Breast Cancer Res. Treat 119(2), 367-367 (2010).
161. Gorbenko O, Panayotou G, Zhyvoloup A, Volkova D, Gout I, Filonenko V. Identification of novel PTEN-binding partners: PTEN interaction with fatty acid binding protein FABP4. Mol. Cell. Biochem. 337(1-2), 299-305 (2010).
162. Tsuda M, Inoue-Narita T, Suzuki A, Itami S, Blumenberg M, Manabe M. Induction of gene encoding FABP4 in Pten-null keratinocytes. FEBS Lett. 583(8), 1319-1322 (2009).
163. Horie Y, Suzuki A, Kataoka E et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 113(12), 1774-1783 (2004). (Pubitemid 39071669)
164. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13(5), 283-296 (2012).
165. Ortega-Molina A, Serrano M. PTEN in cancer, metabolism, and aging. Trends Endocrinol. Metab. 24(4), 184-189 (2012).
166. Koul D, Yao Y, Abbruzzese JL, Yung WK, Reddy SA. Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway. J. Biol. Chem. 276(14), 11402-11408 (2001). (Pubitemid 38089333)
167. Koide S, Okazaki M, Tamura M et al. PTEN reduces cuff-induced neointima formation and proinflammatory cytokines. Am. J. Physiol. Heart Circ. Physiol. 292(6), H2824-H2831 (2007). (Pubitemid 47084532)
168. Li LM, Hou DX, Guo YL et al. Role of microRNA-214-targeting phosphatase and tensin homolog in advanced glycation end product-induced apoptosis delay in monocytes. J. Immunol. 186(4), 2552-2560 (2011).
169. Nigrovic P, Mannion M, Prince F et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 63(2), 545-555 (2011).
170. Dinarello CA. Blocking interleukin-1beta in acute and chronic autoinflammatory diseases. J. Intern. Med. 269(1), 16-28 (2011).
171. Cavelti-Weder C, Babians-Brunner A, Keller C et al. Effects of gevokizumab on glycemia and inflammatory markers in Type 2 diabetes. Diabetes Care 35(8), 1654-1662 (2012).
172. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 13(4), 343-351 (2012).
173. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318(20), 1315-1321 (1988).
174. Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin. Investig. Drugs 17(7), 983-996 (2008).
175. Cocchietto M, Zorzin L, Toffoli B et al. Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy. Diabetes Metab. 34(6 Pt 1), 587-594 (2008).
176. Chandra KP, Shiwalkar A, Kotecha J et al. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects. Clin. Drug Investig. 29(9), 559-575 (2009).
177. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13(17), 1971-1978 (2006).
178. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 25(3), 206-212 (2011).
179. Puddu A, Mach F, Nencioni A, Viviani GL, Montecucco F. An emerging role of glucagon-like Peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. Mediators Inflamm. 591056 (2013).
180. Hui X, Li H, Zhou Z et al. Adipocyte fatty acid-binding protein modulates inflammatory responses in macrophages through a positive feedback loop involving c-Jun NH2-terminal kinases and activator protein-1. J. Biol. Chem. 285(14), 10273-10280 (2010).
181. Lee MY, Li H, Xiao Y, Zhou Z, Xu A, Vanhoutte PM. Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br. J. Pharmacol. 162(7), 1564-1576 (2011).
182. Lin W, Huang X, Zhang L et al. BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase. PLoS ONE 7(8), e44570 (2012).
183. Lan H, Cheng C, Kowalski T et al. Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesity. J. Lipid Res. 52(4), 646-656 (2011).
184. Xu Q, Huang L, Liu J et al. Design, synthesis and biological evaluation of thiazole-and indole-based derivatives for the treatment of Type II diabetes. Eur. J. Med. Chem. 52, 70-81 (2012).
185. Sorci G, Riuzzi F, Giambanco I, Donato R. RAGE in tissue homeostasis, repair and regeneration. Biochem. Biophys. Acta 1833(1), 101-109 (2012).
186. Calle E, Thun M. Obesity and cancer. Oncogene 23, 6365-6378 (2004). (Pubitemid 39265505)
187. Hursting SD, Dunlap SM. Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. Ann. NY Acad. Sci. 1271, 82-87 (2012).
188. Ondrey F. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin. Cancer Res. 15(1), 2-8 (2009).
189. Gul A, Tugal-Tutkun I, Dinarello CA et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann. Rheum. Dis. 71(4), 563-566 (2012).
190. Chen Y, Akirav EM, Chen W et al. RAGE ligation affects T cell activation and controls T cell differentiation. J. Immunol. 181(6), 4272-4278 (2008).
191. Feng B, Xu L, Wang H et al. Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Biochim. Biophys. Acta 1812(9), 1130-1137 (2011).
192. Roan JN, Fang SY, Chang SW et al. Rosuvastatin improves vascular function of arteriovenous fistula in a diabetic rat model. J. Vasc. Surg. 56(5), 1381-1389 (2012).